Clay Siegall, the ex-CEO of SGEN, is the CEO of Morphimmune and will become the CEO of the merged company. After taking into account Siegall’s stock options, existing Morphimmune shareholders will own more than half of the merged company on a fully-diluted basis, which is why this deal should be considered a reverse-merger.